Literature DB >> 8783805

DNA polymerase activity of hepatitis B virus particles: differential inhibition by L-enantiomers of nucleotide analogs.

M G Davis1, J E Wilson, N A VanDraanen, W H Miller, G A Freeman, S M Daluge, F L Boyd, A E Aulabaugh, G R Painter, L R Boone.   

Abstract

DNA polymerase activity was assayed in hepatitis B virus (HBV) and core particles isolated from chronic producer lines. The particle-associated DNA polymerase activity, which was found to be limited to incorporation of only a few nucleotides, was inhibited by the 5'-triphosphates of nucleoside analogs. The 1-beta-L (1S,4R) and 1-beta-D (1R,4S) enantiomers of antiviral nucleoside analogs were compared for the ability to inhibit incorporation of natural nucleoside triphosphates into the viral DNA. Previously, both enantiomers of several analogs were found to be substrates for human immunodeficiency virus type 1 reverse transcriptase (HIV RT); the 1-beta-D enantiomers of some pairs were preferred as substrates. In contrast, the 1-beta-L enantiomers of all pairs tested were the more potent inhibitors of labeled substrate incorporation into hepatitis B virus DNA; the concentration required to inhibit the incorporation of the natural substrate by 50% was 6-fold to several hundred-fold lower than the concentration of the 1-beta-D enantiomer required for the same inhibitory effect. This preference for the 1-beta-L enantiomers was observed for both RNA-directed synthesis in core particles and DNA-directed synthesis in viral particles. The observed antiviral effect of the nucleoside analogs in cell culture seemed to be limited chiefly by their phosphorylation in cells.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8783805     DOI: 10.1016/0166-3542(96)00938-2

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  7 in total

1.  Strong and selective inhibitors of hepatitis B virus replication among novel N4-hydroxy- and 5-methyl-beta-L-deoxycytidine analogues.

Authors:  E Matthes; A Funk; I Krahn; K Gaertner; M von Janta-Lipinski; L Lin; H Will; H Sirma
Journal:  Antimicrob Agents Chemother       Date:  2007-04-02       Impact factor: 5.191

2.  In vivo antiviral activity and pharmacokinetics of (-)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine in woodchuck hepatitis virus-infected woodchucks.

Authors:  J M Cullen; S L Smith; M G Davis; S E Dunn; C Botteron; A Cecchi; D Linsey; D Linzey; L Frick; M T Paff; A Goulding; K Biron
Journal:  Antimicrob Agents Chemother       Date:  1997-10       Impact factor: 5.191

3.  Kinetic analysis of wild-type and YMDD mutant hepatitis B virus polymerases and effects of deoxyribonucleotide concentrations on polymerase activity.

Authors:  Richard K Gaillard; Jennifer Barnard; Vincent Lopez; Paula Hodges; Eric Bourne; Lance Johnson; Marchelle I Allen; Patrick Condreay; Wayne H Miller; Lynn D Condreay
Journal:  Antimicrob Agents Chemother       Date:  2002-04       Impact factor: 5.191

4.  Generation of replication-competent hepatitis B virus nucleocapsids in insect cells.

Authors:  M Seifer; R Hamatake; M Bifano; D N Standring
Journal:  J Virol       Date:  1998-04       Impact factor: 5.103

5.  Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus.

Authors:  S F Innaimo; M Seifer; G S Bisacchi; D N Standring; R Zahler; R J Colonno
Journal:  Antimicrob Agents Chemother       Date:  1997-07       Impact factor: 5.938

6.  Efficacy of the carbocyclic 2'-deoxyguanosine nucleoside BMS-200475 in the woodchuck model of hepatitis B virus infection.

Authors:  E V Genovesi; L Lamb; I Medina; D Taylor; M Seifer; S Innaimo; R J Colonno; D N Standring; J M Clark
Journal:  Antimicrob Agents Chemother       Date:  1998-12       Impact factor: 5.938

7.  In vitro inhibition of hepadnavirus polymerases by the triphosphates of BMS-200475 and lobucavir.

Authors:  M Seifer; R K Hamatake; R J Colonno; D N Standring
Journal:  Antimicrob Agents Chemother       Date:  1998-12       Impact factor: 5.938

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.